SRL
XLO icon

Scientech Research LLC’s Xilio Therapeutics XLO Stock Holding History

Scientech Research LLC’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,039
Closed -$30.8K – 893
2025
Q1 		$30.8K Buy
+3,039
New +$38.2K 0.01% 527

Other funds holding XLO

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GCM
Ghisallo Capital Management Boston, Massachusetts $3.63B AUM 30.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIIC
AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Scientech Research LLC's XLO Position: Q2 2025 in Review

Scientech Research LLC sold out of Xilio Therapeutics (XLO) in Q2 2025, closing a stake of 3,039 shares — an estimated $30.8K sold.

Scientech Research LLC first reported a position in XLO in Q1 2025 and held it in 1 quarter. The position peaked at $30.8K in Q1 2025. 35 funds tracked by Wall St. Rank hold XLO as of Q2 2025.

  • Scientech Research LLC reported no remaining Xilio Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Scientech Research LLC sold 3,039 Xilio Therapeutics shares in Q2 2025, an estimated $30.8K.
  • Scientech Research LLC first reported a position in Xilio Therapeutics in Q1 2025 and held it in 1 quarter.
  • Scientech Research LLC's Xilio Therapeutics position peaked at $30.8K in Q1 2025.
  • 35 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q2 2025.

Based on Scientech Research LLC's 13F filing for Q2 2025, filed 14 Aug 2025.